For Lilly, cash-pay is key in the US and, increasingly, abroad
Eli Lilly already knows Americans are willing to shell out hundreds of dollars a month for obesity drugs. Its bet on selling directly to patients helped it build a substantial
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.